{
    "nct_id": "NCT04006457",
    "official_title": "A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA",
    "inclusion_criteria": "Inclusion Criteria-\n\nFor de novo participants and participants from Study B7931005 and B7981015 with >30 days between first visit in B7981032 and last dose in the prior study:\n\n* Clinical diagnosis of alopecia areata (AA) with no other cause of hair loss. Androgenetic alopecia coexistent with AA is allowed.\n* De novo participants >=12 to <18 years of age: >=50% terminal hair loss of the scalp due to AA, including alopecia totalis and alopecia universalis\n* De novo participants >=18 years of age and participants from Study B7931005 or B7981015 with >30 days between first visit in B7981032 and last dose in the prior study: >=25% terminal hair loss of the scalp due to AA, including alopecia totalis and alopecia universalis\n* No evidence of terminal scalp hair regrowth within 6 months (de novo only)\n* Current episode of terminal scalp hair loss <=10 years (de novo only)\n\nExclusion Criteria-\n\nFor de novo participants and participants from Study B7931005 and B7981015 with >30 days between first visit in B7981032 and last dose in the prior study:\n\n* Hearing loss with progression over previous 5 years, or sudden hearing loss, or middle or inner ear disease, or other auditory condition that is considered acute, fluctuating or progressive\n* History of or current malignancies with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ\n* History of a single episode of disseminated herpes zoster or disseminated herpes simplex, or a history of more than one episode of localized, dermatomal herpes zoster\n* Infection requiring hospitalization, or parenteral antimicrobial therapy within 6 months prior to Day 1\n\nExclusion criteria for all participants:\n\n- Participants who have previously taken Janus kinase (JAK) inhibitors other than PF-06651600 must have received the last dose >12 weeks prior to the screening visit\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}